Ron Bentsur

Chairman & CEO at Nuvectis Pharma · 3 reported transactions in 1 company · latest trade Jun 30, 2026

Their record

Across their whole record, 1 purchase can be measured; 1 did better than the S&P 500 over the next 6 months.

Typical move +51.5%, S&P 500 +6.1% over the same days.

1 more is too recent to measure.


Nuvectis PharmaNVCT	Bought $250K · 12,500 shares	Jun 30, 2026	S&P 500 +3.4%thru Oct 28
Nuvectis PharmaNVCT	Bought $28.6K · 5,000 shares	Nov 5, 2025	S&P 500 +14.0%thru Oct 28

Jun 30, 2026 · NVCT

$250K

S&P 500 +3.4%thru Oct 28

Nov 5, 2025 · NVCT

$28.6K

S&P 500 +14.0%thru Oct 28

3 transactionsPro adds every trade with how it did, their holdings and the money-flow chartPro is $29 a month

Built from their public trade reports and market prices: past moves, not predictions or advice.